300239 Baotou Dongbao Bio-tech
- 5.73
- +0.49+9.35%
Baotou Dongbao Bio-tech News
Dongbao Biotech (300239): Gelatin and by-products business grew steadily, Yiqing Biotech added a new capsule production capacity of 15 billion capsules/year
In '23, revenue increased 3.30% year over year, and net profit to mother increased 9.55%. The company achieved operating income of 975 million yuan in 2023, +3.30% year-on-year; realized net profit of 120 million yuan, +9 million yuan year-on-year.
Dongbao Biotech (300239.SZ) announced its 2023 annual results, with net profit of 120 million yuan, an increase of 9.55%
Dongbao Biotech (300239.SZ) released its 2023 annual report. During the reporting period, the company achieved an operating income of 9...
Dongbao Biotech (300239.SZ): Net profit of 259.615 million yuan in the first quarter decreased 16.62% year-on-year
Gelonghui, April 23 | Dongbao Biotech (300239.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 242 million yuan, down 7.48% year on year; net profit attributable to shareholders of listed companies was 25.9615 million yuan, down 16.62% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 236.22,300 yuan, down 21.61% year on year; basic earnings per share were 0.0437 yuan.
The A-share artificial meat concept fluctuated and declined, Dongbao Biotech fell more than 6%
Gelonghui March 1 | Dongbao Biotech and Shuangta Foods fell more than 6%, followed by Zuming Co., Ltd., Suobao Protein, Tangrenshen, and Jiahua Co., Ltd.
Dongbao Biotech (300239.SZ): The subsidiary Yiqing Biotech has once again been certified as a high-tech enterprise
Gelonghui, Feb. 20, | Dongbao Biotech (300239.SZ) announced that the company's holding subsidiary, Qingdao Yiqing Biotechnology Co., Ltd. (“Yiqing Biotech”), recently received the “High-tech Enterprise Certificate” jointly approved and issued by the Qingdao Municipal Bureau of Science and Technology, the Qingdao Municipal Finance Bureau, and the Qingdao Municipal Taxation Bureau of the State Administration of Taxation. Yiqing Biotech has once again passed the high-tech enterprise certification.
Dongbao Biotech (300239.SZ) once again passed the high-tech enterprise certification
Gelonghui, January 23丨Dongbao Biotech (300239.SZ) announced that the company recently received the “High-tech Enterprise Certificate” jointly approved and issued by the Inner Mongolia Autonomous Region Science and Technology Department, the Inner Mongolia Autonomous Region Finance Department, and the Inner Mongolia Autonomous Region Taxation Bureau of the State Administration of Taxation. The company once again passed the high-tech enterprise certification.
Toho Biotech (300239.SZ): Main products gelatin, collagen, capsules and terminal series products, etc.
Glonghui December 18丨Dongbao Biotech (300239.SZ) said on the investor interactive platform that the company's main products include gelatin, collagen, capsules and terminal products, etc., which are widely used in food, pharmaceuticals, health products, beauty and other fields. The company's collagen series products are basic nutrition and health products, mainly targeting middle-aged and elderly markets, women's markets, bone health markets, and sub-health markets.
Dongbao Biotech (300239.SZ): Business cooperation with existing customers of plasma gelatin is developing normally, and the capsule business is being produced at full capacity
Glonghui, December 13|An investor asked Dongbao Biotech (300239.SZ) on the investor interactive platform, “How is the company's product production and sales? Has the price of gelatin fluctuated, and are there any new developments in the company's plasma replacement products? Has the production of medicinal capsules expired recently?” The company replied that the production and sales of the company's main products are normal. Please also pay attention to the regular reports disclosed by the company for specific operating data. Business cooperation with existing customers of plasma gelatin is being carried out normally, and the capsule business is being produced at full capacity.
Toho Biotech (300239.SZ): The company is not involved in computing power business
Gelonghui November 17丨Dongbao Biotech (300239.SZ) stated on the investor interactive platform that the company is not involved in computing power business.
Dongbao Biotech (300239): Net profit from mother in the first three quarters increased by +9% compared to the same period, gross margin increased by nearly 1PCT
Revenue for the first three quarters was +4.05% yoy, and net profit was +8.52% yoy. In the first three quarters of 2023, the company achieved a total operating income of 735 million yuan, an increase of 4.05% over the previous year; net profit of 95 million yuan was realized, same
Toho Biotech (300239.SZ): The company currently has no restructured collagen business
Gelonghui November 2: Some investors asked Dongbao Biotech (300239.SZ) on the investor interactive platform. “Does the company have recombinant collagen technology?” The company stated that the company has not restructured its collagen business at present.
Toho Biotech (300239.SZ): Does not produce diet pills or fitness equipment
On November 2, some investors asked Dongbao Biotech (300239.SZ) on the investor interactive platform, “Does your company have R&D pharmaceuticals for diseases such as mammary glands, dermatitis, joints, epilepsy, tumors, cancer, genetic mitochondria, etc., as well as health care products such as diet pills and fitness equipment.” The company stated that the company's main products are gelatin, plasma substitutes, collagen, hollow capsules, and TOC series, which are widely used in downstream biomedicine, pharmaceuticals, health products, functional foods, and beauty products. The company does not produce pharmaceuticals, diet pills or fitness equipment.
Dongbao Biotech (300239.SZ) released the first three quarter results, net profit of 95261,700 yuan, an increase of 8.52%
Dongbao Biotech (300239.SZ) released its report for the third quarter of 2023. The company's revenue for the first three quarters was 7...
Dongbao Biotech (300239.SZ): The company does not produce collagen type 17
Glonghui, Oct. 26丨Dongbao Biotech (300239.SZ) stated on the investor interactive platform that the company does not produce type 17 collagen.
Dongbao Biotech (300239.SZ): Plasma-substituted gelatin is mainly used in the medical and pharmaceutical fields. Currently used in the production of injectable polygelatin peptides and succinyl gelatin injections
Glonghui, September 27丨Dongbao Biotech (300239.SZ) said on the investor interactive platform that gelatin is widely used in health products/nutritional health food fields such as candy (including gummies), dairy products, popsicles, meat products, baking, compound emulsifiers, beverages, ice cream, softgels, etc., and is currently used in the field of medical pharmaceuticals (regenerative medicine materials, etc.). Currently, it is used in the production of polygelatin peptides and succinyl gelatin injections. It can also be widely used in hemostatic sponges, gels, microneedles, microspheres, etc. production. Plasma-substituted gelatin products are different in price from other gelatin products and fall into the category of gelatin
Dongbao Biotech (300239): 23H1 Gimu's net profit was +12.12% year-on-year, continuing to promote industrial chain integration
2023H1 achieved revenue of 521 million yuan and net profit of 65 million yuan. The company achieved operating income of 521 million yuan in the first half of 2023, +9.31% year-on-year; net profit of 0.65
Dongbao Biotech (300239.SZ) released first-half results, net profit of 65.041 million yuan, an increase of 12.12%
Dongbao Biotech (300239.SZ) released the 2023 semi-annual report. The company's revenue was 521 million...
Baotou Dongbao Bio-Tech Raises 455 Million Yuan From Bond Sale
Baotou Dongbao Bio-Tech (SHE:300239) has raised 455 million yuan from the sale of convertible bonds, according to a filing on Friday. The Chinese producer of collagen products issued 4.55 million bond
Toho Biotech (300239.SZ) revealed the winning results of convertible bonds: there were a total of 1981.32 million winning numbers
On August 1, GLONGHUI | TOBao Biotech (300239.SZ) announced the issuance of convertible corporate bond winning numbers to unspecified targets. The details are as follows: Any investor participating in the online subscription of Toho Bonds Convertible holds the same number as the number above, the winning number is the winning number. There are a total of 1981.32 million winning numbers, and each winning number can only subscribe for 10 cards (1,000 yuan) of Toho debt conversion.
Toho Biotech (300239.SZ): “Toho Bonds Transfer” will open a subscription on July 31
According to the Zhitong Finance App, Dongbao Biotech (300239.SZ) announced the issuance of convertible corporate bonds to unspecified targets. The convertible corporate bonds issued this time are called “Toho Convertible Bonds” for short, and the bond code is “123214.” The priority placement date for the original shareholders of this convertible bond issue is July 31, 2023 (T-day), the same as the online purchase date. The number of Toho Convertible Bonds that the original shareholders can prioritize placement is the number of shares they registered to hold in Dongbao Biotech after the market closes on the stock registration date (July 28, 2023, T-1), calculated as a ratio of 0.7665 yuan of convertible bonds per share to be placed
Analysis
Price Target
No Data
